-2%
Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by selectively inhibiting the H⁺/K⁺-K-ATPase enzyme in the gastric parietal cells.
This inhibition blocks the final step of acid production, thereby reducing gastric acidity effectively.
It is the R-enantiomer of lansoprazole, formulated as a Dual Delayed Release (DDR) capsule containing two types of enteric-coated granules that dissolve at different pH levels.
This unique release profile results in two plasma concentration peaks — the first within 1–2 hours, and the second within 4–5 hours after administration.
Dexlansoprazole is extensively metabolized in the liver and primarily excreted through urine.
Lasocon D (Dexlansoprazole)
Therapeutic Class: Proton Pump Inhibitor (PPI)
- 1. Healing of Erosive Esophagitis (EE):
Indicated for the healing of all grades of erosive esophagitis for up to 8 weeks. - 2. Maintenance of Healed Erosive Esophagitis:
Used to maintain the healing of EE and provide relief from heartburn for up to 6 months. - 3. Symptomatic Non-Erosive GERD:
Indicated for the treatment of heartburn associated with symptomatic non-erosive Gastroesophageal Reflux Disease (GERD) for up to 4 weeks.